Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy
Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy
复制标题
DOI：
10.1002/jmv.26459
复制
发表时间：
2020-09-30
影响因子：
12.7
通讯作者：
d'Arminio Monforte, Antonella
中科院分区：
文献类型：
--
作者：
Tomasoni, Daniele;Bai, Francesca;d'Arminio Monforte, Antonella
采用医院焦虑抑郁量表(HADS-A/D)对105例新冠肺炎患者在病毒学清除后1~3个月的焦虑或抑郁状况进行调查。30%的患者表现为病理性HADS-A/D，52.4%的患者有持续性症状。患有HADS-A/D的病理性患者报告的症状持续性更常见，即使在调整了年龄、性别和疾病严重程度后也是如此。在新冠肺炎患者的随访中应鼓励心理评估。
Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID-19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS-A/D). 30% of patients displayed pathological HADS-A/D, 52.4% showed persistent symptoms. Pathological patients with HADS-A/D more commonly reported symptom persistence, even after adjustment for age, gender, and disease severity. Psychological assessments should be encouraged in COVID-19 patients' follow-up.